Drug Trial Radar · NCT06616194
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
636
Planned (sponsor's estimate)
Start
Nov 15, 2024
Primary completion
Feb 26, 2030
Study completion Apr 22, 2031
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that disintegrates when you put it on or under your tongue. The study will enroll participants who have headache for 15 days (or more) every month, of which 8 days (or more) of migraine every month, and each untreated attack lasts for an average of 4-72 hours In the 1st part of the study approximately half of the participants will receive a rimegepant tablet every other day, and approximately half of the participants will receive an inactive oral tablet (that looks the same as the rimegepant tablet) every other day. Participant experiences when they are taking the study medicine will be compared to when they are taking the inactive tablet. This will help to determine if the study medicine is safe and effective. The 1st phase of the study will last 3 months. In the 2nd part of the study all the participants who stay on study will receive rimegepant tablet every other day. This 2nd phase of the study will last 1 year. This will help determine if the study medicine is safe when taken for a long period. Those who will participate in both phases will have up to 19 visits at the study clinic, about one every 4 weeks (this may vary from 2 to 8 weeks interval during the study). Home health visits may occur as well. A health check and blood sample will be conducted at the study clinic visits. Participants will have to complete a daily diary to record the migraine attacks.
Conditions
- Migraine
Interventions
RimegepantDrug
Rimegepant 75 mg orally disintegrating tablets
PlaceboDrug
Matching placebo oral disintegrating tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of migraine days per monthTime frame: 12 Weeks
Locations
102 sites in 12 countries. Site status is shown where the registry gives one.
Xenoscience Inc
Phoenix, Arizona
Adult & Child Neurology Medical Associates
Long Beach, California
Children's Hospital Colorado
Aurora, Colorado
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Chicago Headache Center and Research Institute
Chicago, Illinois
Chicago Headache Center and Research Institute
Naperville, Illinois
New England Regional Headache Center
Worcester, Massachusetts
Michigan Headache & Neurological Institute
Ann Arbor, Michigan
Clinvest Headlands Llc
Springfield, Missouri
Rutgers University
New Brunswick, New Jersey
OnSite Clinical Solutions
Charlotte, North Carolina
Duke Health Center Creekstone
Durham, North Carolina
Duke Lenox Baker Children's
Durham, North Carolina
Duke Children's Health Center
Durham, North Carolina
Wake Forest University Baptist Medical Center ( WFUBMC )
Winston-Salem, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Avera Medical Group Pediatric Specialists
Sioux Falls, South Dakota
Avera Research Institute - Sioux Falls
Sioux Falls, South Dakota
Avera Medical Group Pediatrics - Dawley Farm
Sioux Falls, South Dakota
Dell Children's Medical Center
Austin, Texas
Headlands-EI Paso
El Paso, Texas
The University of Texas Health Science Center at Houston
Houston, Texas
Wasatch Clinical Research, LLC
Salt Lake City, Utah
Granger Medical Holladay - Holladay Clinic
Salt Lake City, Utah
Seattle Children's Hospital
Seattle, Washington
University Of Alberta Hospital
Edmonton, Alberta, Canada
Stollery Children's Hospital
Edmonton, Alberta, Canada
CaRe Clinic
Red Deer, Alberta, Canada
London Health Sciences Centre - Verspeeten Family Cancer Centre
London, Ontario, Canada
Anhui Provincial Hospital
Hefei, China
Shanghai Children's Hospital
Shanghai, China
The Second Affiliated Hospital of Hebei Medical University
Shijiazhuang, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
Jingzhou First People's Hospital
Jingzhou, Hubei, China
Wuhan Children's Hospital
Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.